ADC2GBM (Development of brain-permeable masked nanobody-drug conjugates to eliminate glioma stem cells)
Innovative formulation to treat glioma using brain-permeable masked nanobody-drug conjugates.
Funding Sources:
European Union
European Union
Funding Agency:
Type of Project:
Individual project
Individual project
Period:
01/05/2022 a 30/04/2024
01/05/2022 a 30/04/2024
Funding:
165.312€
165.312€
Project current status:
ACTIVE
ACTIVE
The main objective of this proposal is to develop a masked nanobody-drug conjugate with the capacity to overcome the BBB and to be activated only in the tumour to selectively target GSCs.
The concept of GSC-targeting with activatable ADC may change the current paradigm for the treatment of brain tumours. Furthermore, our workflow may be applied to dramatically enhance the efficacy of other biotherapeutics with on-target off-site dose-limiting effects.
PRIMARY INVESTIGATOR
Benjamí Oller-Salvia, PhD
Associate Professor - Junior Leader F. La Caixa - ERC Grantee
+34932672000
SEE MORE
LINKED NEWS
Interview
Producing masked antibodies through targeted evolution
01/09/2022
“In the ADC2GBM project, we're combining our experience in targeted evolution and antibody engineering to develop activatable antibody-drug conjugates for the treatment of glioblastoma multiforme”
READ FULL NEW
7 Questions for...
Cristina Díaz
12/05/2022
Interview to Dr Cristina Díaz, researcher with the GEMAT group at the IQS School of Engineering.
READ FULL NEW
RESEARCH GROUP
School of Engineering
Materials Engineering
Its activities focus on three main areas: the development of new functional materials, surface engineering and biomaterials.
School of Engineering
Chemical & Synthetic Biology for Biotherapies
This group combines chemistry and synthetic biology to develop precision bio-nano-therapeutics based on smart proteins and to generate molecular systems that enable transport of therapeutics to the brain.
